Previous 10 | Next 10 |
Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually DEER PARK, Ill., June 13, 2019 (GLOBE ...
Introduction to Harrow Health Inc. Harrow Health, Inc. ( HROW ) owns a diversified portfolio of healthcare businesses, including the nation's leading ophthalmic pharmaceutical compounding business, ImprimisRx®. The company holds large equity positions in Eton Pharmaceuticals ( ETON ), S...
DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 20 th Annua...
The following slide deck was published by Eton Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Eton Pharmaceuticals, Inc. (ETON) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants David Krempa – Vice President-Business Development Sean Brynjelsen – Chief Executive Officer Wilson Troutman – Chief Financial Officer Conference...
Eton Pharmaceuticals (NASDAQ: ETON ): Q1 GAAP EPS of -$0.42. More news on: Eton Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Four Products Currently Under Review with the FDA – – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at 4:30 p.m. ET (3:30 p.m. CT) - DEER PARK, Ill., May 07, 2019 (GL...
DEER PARK, Ill., April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating results on Tue...
Eton Pharmaceuticals (NASDAQ: ETON ): Q4 GAAP EPS of -$2.24. Cash and cash equivalents of $26.74M. Press Release More news on: Eton Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
DEER PARK, Ill., March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the fourth quarter and full year ended December 31, 2018 and p...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...